
Understanding FLT3 in AML: What It Means and How It’s Treated
Join us for a special session focused on FLT3 mutations in Acute Myeloid Leukemia (AML), one of the most common genetic changes found in AML patients. Dr. Nicholas Short from MD Anderson Cancer Center will explain what FLT3 mutations are, how they affect treatment decisions, and what targeted therapies are available today. Whether you’re newly diagnosed or navigating ongoing treatment, this session will help you understand the role FLT3 plays in your AML journey and what questions to ask your doctor.
Marilu introduces the agenda for the event and featured speaker Dr. Nicholas Short
Dr. Short talks about FLT3 mutations in AML
Type your questions in the chat and we will answer them!

Marilu N Flores
In-Person Event Operations Manager, HealthTree Foundation

Nicholas Short, MD